UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

The New England journal of medicine, 2022-03, Vol.386 (12), p.1132-1142

2022

Volltextzugriff (PDF)

MicroRNA expression profiling in prostate cancer

Cancer research (Chicago, Ill.), 2007-07, Vol.67 (13), p.6130-6135

2007

Volltextzugriff (PDF)

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

The New England journal of medicine, 2009-08, Vol.361 (8), p.745-755

2009

Volltextzugriff (PDF)

What Is the Most Bothersome Lower Urinary Tract Symptom? Individual- and Population-level Perspectives for Both Men and Women

European urology, 2014-06, Vol.65 (6), p.1211-1217

2014

Volltextzugriff (PDF)

Screening and Prostate-Cancer Mortality in a Randomized European Study

The New England journal of medicine, 2009-03, Vol.360 (13), p.1320-1328

2009

Volltextzugriff (PDF)

Silodosin Therapy for Lower Urinary Tract Symptoms in Men with Suspected Benign Prostatic Hyperplasia: Results of an International, Randomized, Double-Blind, Placebo- and Active-Controlled Clinical Trial Performed in Europe

European urology, 2011-03, Vol.59 (3), p.342-352

2011

Volltextzugriff (PDF)

Nocturia Frequency, Bother, and Quality of Life: How Often Is Too Often? A Population-Based Study in Finland

European urology, 2010-03, Vol.57 (3), p.488-498

2010

Volltextzugriff (PDF)

The Role of Genetic Markers in the Management of Prostate Cancer

European urology, 2012-10, Vol.62 (4), p.577-587

2012

Volltextzugriff (PDF)

Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer

European urology, 2015-11, Vol.68 (5), p.885-890

2015

Volltextzugriff (PDF)

Antihypertensive drug use and prostate cancer-specific mortality in Finnish men

PloS one, 2020-06, Vol.15 (6), p.e0234269-e0234269

2020

Volltextzugriff (PDF)

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up

The Lancet (British edition), 2014-12, Vol.384 (9959), p.2027-2035

2014

Volltextzugriff (PDF)

Prostate cancer risk prediction using a polygenic risk score

Scientific reports, 2020-10, Vol.10 (1), p.17075-17075, Article 17075

2020

Volltextzugriff (PDF)

Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer

Journal of clinical oncology, 2012-09, Vol.30 (26), p.3271-3276

2012

Volltextzugriff (PDF)

The importance of LDL and cholesterol metabolism for prostate epithelial cell growth

PloS one, 2012-06, Vol.7 (6), p.e39445-e39445

2012

Volltextzugriff (PDF)

Screening history and risk of death from prostate cancer: a nested case–control study within the screening arm of the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC)

Cancer causes & control, 2024-04, Vol.35 (4), p.695-703

2024

Volltextzugriff (PDF)

Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level

European journal of cancer (1990), 2013-03, Vol.49 (4), p.938-945

2013

Volltextzugriff (PDF)

Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression

Nature communications, 2018-03, Vol.9 (1), p.1176-13, Article 1176

2018

Volltextzugriff (PDF)

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

European urology, 2017-02, Vol.71 (2), p.151-154

2017

Volltextzugriff (PDF)

Prostate-Cancer Mortality at 11 Years of Follow-up

The New England journal of medicine, 2012-03, Vol.366 (11), p.981-990

2012

Volltextzugriff (PDF)

Cholesterol-Lowering Drugs and Prostate Cancer Risk: A Population-based Case-Control Study

Cancer epidemiology, biomarkers & prevention, 2007-11, Vol.16 (11), p.2226-2232

2007

Volltextzugriff (PDF)

TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis

Clinical cancer research, 2008-06, Vol.14 (11), p.3395-3400

2008

Volltextzugriff (PDF)

Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data

PloS one, 2019-11, Vol.14 (11), p.e0224479-e0224479

2019

Volltextzugriff (PDF)

Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus

Cell, 2018-07, Vol.174 (3), p.576-589.e18

2018

Volltextzugriff (PDF)

AR and ERG drive the expression of prostate cancer specific long noncoding RNAs

Oncogene, 2020-07, Vol.39 (30), p.5241-5251

2020

Volltextzugriff (PDF)

Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy—A Randomized, Double-blind, Placebo-controlled Clinical Trial

European urology, 2018-12, Vol.74 (6), p.697-701

2018

Volltextzugriff (PDF)

1 – 25 von 671

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(623)
Mit Volltextzugriff
(496)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(471)
Life Sciences & Biomedicine
(456)
Humans
(423)
Male
(419)
Middle Aged
(264)
Aged
(263)
Biological And Medical Sciences
(243)
Urology & Nephrology
(241)
Medical Sciences
(238)
Prostate Cancer
(189)
Nephrology. Urinary Tract Diseases
(173)
Urinary Tract. Prostate Gland
(158)
Oncology
(138)
Tumors Of The Urinary System
(124)
Urology
(110)
Tumors
(106)
Finland - Epidemiology
(94)
Aged, 80 And Over
(93)
Prostatic Neoplasms - Genetics
(89)
Prostatic Neoplasms - Pathology
(86)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

MicroRNA expression profiling in prostate cancer

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

What Is the Most Bothersome Lower Urinary Tract Symptom? Individual- and Population-level Perspectives for Both Men and Women

Screening and Prostate-Cancer Mortality in a Randomized European Study

Silodosin Therapy for Lower Urinary Tract Symptoms in Men with Suspected Benign Prostatic Hyperplasia: Results of an International, Randomized, Double-Blind, Placebo- and Active-Controlled Clinical Trial Performed in Europe

Nocturia Frequency, Bother, and Quality of Life: How Often Is Too Often? A Population-Based Study in Finland

The Role of Genetic Markers in the Management of Prostate Cancer

Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer

Antihypertensive drug use and prostate cancer-specific mortality in Finnish men

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up

Prostate cancer risk prediction using a polygenic risk score

Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer

The importance of LDL and cholesterol metabolism for prostate epithelial cell growth

Screening history and risk of death from prostate cancer: a nested case–control study within the screening arm of the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC)

Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level

Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

Prostate-Cancer Mortality at 11 Years of Follow-up

Cholesterol-Lowering Drugs and Prostate Cancer Risk: A Population-based Case-Control Study

TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis

Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data

Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus

AR and ERG drive the expression of prostate cancer specific long noncoding RNAs

Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy—A Randomized, Double-blind, Placebo-controlled Clinical Trial

Suchergebnisse filtern